Last reviewed · How we verify
Blinatumomab Injection (blinatumomab-injection)
At a glance
| Generic name | blinatumomab-injection |
|---|---|
| Sponsor | Pfizer Inc. |
| Modality | Monoclonal antibody |
| Phase | Phase 2 |
Approved indications
Common side effects
- Anaemia
- Pyrexia
- Cytokine release syndrome
- White blood cell count decreased
- Hypokalaemia
- Lymphocyte count decreased
- Neutrophil count decreased
- C-reactive protein increased
- Platelet count decreased
- Blood lactate dehydrogenase increased
- Thrombocytopenia
- Leukopenia
Key clinical trials
- Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia (NA)
- A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL (PHASE1, PHASE2)
- A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia (PHASE3)
- A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases (PHASE2)
- A Study of Inotuzumab and Blinatumomab in People With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia (PHASE2)
- A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia (PHASE1, PHASE2)
- Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukemia (MPAL) (PHASE2)
- Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Blinatumomab Injection CI brief — competitive landscape report
- Blinatumomab Injection updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI